Sanofi is expanding its neuroscience drug pipeline through the $470 million acquisition(Opens in a new window) of Vigil Neuroscience, a clinical-stage biotech with a...
BioMarin Pharmaceutical is building up its pipeline with the acquisition of Inozyme Pharma in a $270 million deal centered on an enzyme replacement therapy...
Following a strong 2024 business performance, with $1.5 billion in revenue, Kraken released its latest report and other official company announcements. The Kraken Q1...